Loading
A phase 2 trial of Ziv-aflibercept, Irinotecan and Fluorouracil in Colorectal cancer, run by Sanofi, completed.
A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan is a phase 2 interventional study registered as NCT01882868 by Sanofi, with 62 participants recorded, started 2013-07 and reaching its primary completion in 2015-08. Interventions recorded: Aflibercept, Levofolinate, Irinotecan, 5-FU. Conditions recorded: Colorectal Cancer Metastatic.
Linked to the drug Ziv-aflibercept because the registry names it among its interventions and Colorectal cancer among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
62 enrolled.
95% CI 1.3 to 15.3; Figures from the ClinicalTrials.gov results section (first posted 2017-03-14), not from a publication
Source95% CI 11.203 to 19.811; Figures from the ClinicalTrials.gov results section (first posted 2017-03-14), not from a publication
Source95% CI 4.140 to 6.702; Figures from the ClinicalTrials.gov results section (first posted 2017-03-14), not from a publication
SourceShares Irinotecan (and liposomal irinotecan), Fluorouracil (5-FU), Colorectal cancer and the tag pipeline.
Shares Ziv-aflibercept and the tag pipeline.
Shares Irinotecan (and liposomal irinotecan), Fluorouracil (5-FU), Colorectal cancer and the tag pipeline.
Shares Fluorouracil (5-FU), Colorectal cancer and the tag pipeline.
Shares Irinotecan (and liposomal irinotecan), Fluorouracil (5-FU), Colorectal cancer and the tag pipeline.
Shares Irinotecan (and liposomal irinotecan), Fluorouracil (5-FU), Colorectal cancer and the tag pipeline.
Shares Sanofi, Colorectal cancer and the tag pipeline.
Shares Irinotecan (and liposomal irinotecan), Colorectal cancer and the tag pipeline.